Back to results
US 10,280,404 B2Granted
Optimized HCV full-length infectious cell culture systems and applications thereof
AssigneesHvidovre Hospital, Københavns Universitet
InventorsJens Bukh, Yiping Li, Santseharay Ramirez Almeida
Life of this patent
Estimating the term…
Abstract
The present invention relates to nucleic acid sequences that encode hepatitis C viruses (HCV) that are useful in the fundamental research of HCV as well as in the search of a vaccine against HCV. In particular the present invention relates to nucleic acid sequences that comprises HCVs which are capable of expressing said virus when transfected into cells and are capable of infectivity in vivo.
Claims5
An isolated nucleic acid molecule which encodes a human hepatitis C of strain genotype 1a, virus, wherein said molecule:
- (i) is capable of expressing said virus when transfected into cells,
- (ii) is capable of infectivity in vivo,
- (iii) comprises at least one adaptive mutation in the amino acid sequence of NS3, which is F1464L,
- (iv) comprises at least one adaptive mutation in the amino acid sequence of NS4A which is A1672S, and
- (v) comprises at least one adaptive mutation in the amino acid sequence of NS5B which is D2979G, and
- (vi) the following additional adaptive mutations in the amino acid sequence:
- S399F, A970T, I1312V, I1326V, V2198A, 12268T, C2419R, E2622D and A2919T, wherein the positions are according to GenBank accession number AF009606 (SEQ ID NO:
- 7) or the following additional adaptive mutations in the amino acid sequence:
- M345T, A828V, L864R, K1052R, S1368P, V1663A, G1909S, M2105V, S2354G, V2417A and V2431I,
- wherein the positions are according to GenBank accession number AF009606 (SEQ ID NO:7).
7 more elements
Dependencies are inferred from the claim text.